News stories about BioMarin Pharmaceutical (NASDAQ:BMRN) have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioMarin Pharmaceutical earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.8351639179188 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:

Shares of BioMarin Pharmaceutical (BMRN) traded down 0.11% during midday trading on Tuesday, reaching $83.08. The company had a trading volume of 998,533 shares. The company has a 50 day moving average price of $88.37 and a 200-day moving average price of $90.03. BioMarin Pharmaceutical has a one year low of $78.42 and a one year high of $102.06. The firm’s market capitalization is $14.56 billion.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01. The business had revenue of $317.50 million for the quarter, compared to analysts’ expectations of $311.41 million. BioMarin Pharmaceutical had a negative net margin of 15.54% and a negative return on equity of 5.77%. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($2.61) EPS. On average, analysts anticipate that BioMarin Pharmaceutical will post ($0.71) EPS for the current fiscal year.

Several research analysts have recently weighed in on the company. Wedbush reaffirmed a “neutral” rating and set a $108.00 price objective on shares of BioMarin Pharmaceutical in a research report on Monday, August 7th. Deutsche Bank AG set a $105.00 price objective on BioMarin Pharmaceutical and gave the stock a “buy” rating in a research report on Friday, April 28th. BMO Capital Markets reduced their price objective on BioMarin Pharmaceutical from $112.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, April 24th. Jefferies Group LLC reaffirmed a “buy” rating and set a $116.00 price objective on shares of BioMarin Pharmaceutical in a research report on Monday, May 15th. Finally, J P Morgan Chase & Co reaffirmed a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Monday, May 1st. Two analysts have rated the stock with a sell rating, ten have given a hold rating and thirteen have given a buy rating to the company. BioMarin Pharmaceutical has a consensus rating of “Hold” and an average price target of $110.20.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect BioMarin Pharmaceutical (BMRN) Stock Price” was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.watchlistnews.com/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-biomarin-pharmaceutical-bmrn-stock-price/1492648.html.

In other BioMarin Pharmaceutical news, EVP George Eric Davis sold 9,471 shares of the company’s stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $91.04, for a total transaction of $862,239.84. Following the completion of the sale, the executive vice president now directly owns 74,342 shares in the company, valued at $6,768,095.68. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Jean Jacques Bienaime sold 5,000 shares of the company’s stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $88.38, for a total transaction of $441,900.00. Following the sale, the chief executive officer now owns 238,564 shares of the company’s stock, valued at $21,084,286.32. The disclosure for this sale can be found here. Insiders sold 61,740 shares of company stock valued at $5,659,589 over the last quarter. 2.50% of the stock is owned by company insiders.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.